Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial
Open Access
- 30 June 2014
- journal article
- research article
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 12 (1) , 87-95
Abstract
While ovarian cancer (OvCa) responds well to surgery and conventional chemotherapy, a high recurrence rate of advanced OvCa is observed. In this phase I/II study, 10 OvCa patients with minimal residual disease were treated with autologous dendritic cells (DCs) and IL-2 to evaluate the safety and feasibility of this therapeutic strategy and to characterize the antigen-specific immune alterations induced through this treatment. Approximately 4 months after initial debulking and chemotherapy, patients received two subcutaneous doses of autologous monocyte-derived DCs pulsed with autologous tumor lysate and keyhole limpet hemocyanin (KLH) at 4-week intervals. After each DC inoculation, low-dose (200 mIU) IL-2 was introduced for 14 consecutive days as an immune adjuvant. The vaccination was well tolerated. In three out of 10 patients, the inclusion status after the initial therapy showed the maintenance of complete remission (CR) after DC vaccination for 83, 80.9 and 38.2 months without disease relapse. One patient with stable disease (SD) experienced the complete disappearance of tumor after DC vaccination, and this status was maintained for 50.8 months until tumor recurrence. In two patients with partial response (PR) was not responding to DC vaccination and their disease recurred. In the three patients with disease free long-term survival, significant immune alterations were observed, including increased natural killer (NK) activity, IFN-γ-secreting T cells, immune-stimulatory cytokine secretion and reduced immune-suppressive factor secretion after DC vaccination. Thus, in patients with NED status and increased overall survival, DC vaccination induced tumor-related immunity, potentially associated with long-term clinical responses against OvCa.Keywords
This publication has 27 references indexed in Scilit:
- Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancerOncoImmunology, 2013
- Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trialJournal of Translational Medicine, 2011
- Anticancer immune reactivity and long-term survival after treatment of metastatic ovarian cancer with dendritic cellsOncology Letters, 2011
- Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinomaClinical Immunology, 2007
- IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patientsBlood, 2006
- Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Sequential development of interleukin 2–dependent effector and regulatory T cells in response to endogenous systemic antigenJournal of Experimental Medicine, 2005
- Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic CellsJournal of Experimental Medicine, 2004
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coliScience, 1984